Información del artículo
El Texto completo está disponible en PDF
References
[1.]
M. Sodhi, K.H. Wood, J. Meador-Woodruff.
Role of glutamate in schizophrenia: integrating excitatory avenues of research.
Expert Rev Neurother, 8 (2008), pp. 1389-1406
[2.]
G. Remington.
Alterations of dopamine and serotonin transmission in schizophrenia.
Prog Brain Res, 172 (2008), pp. 117-140
[3.]
P.F. Buckley, B. Miller, Douglas Lehrer, D. Castle.
Psychiatric comorbidities and schizophrenia.
Schizophr Bull, 35 (2009), pp. 383-402
[4.]
D. Dickinson, M.E. Ramsey, J.M. Gold.
Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia.
Arch Gen Psychiatry, 64 (2007), pp. 532-542
[5.]
M.F. Green.
Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.
J Clin Psychiatry, 67 (2006), pp. 3-8
[6.]
P.F. Whitty, O. Owoeye, J.L. Waddington.
Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.
Schizophr Bull, 35 (2009), pp. 415-424
[7.]
S.M. Weinberg, E.A. Jenkins, M.L. Marazita, B.S. Maher.
Minor physical anomalies in schizophrenia: a meta-analysis.
Schizophr Res, 89 (2007), pp. 72-85
[8.]
K. Wahlbeck, T. Forsén, C. Osmond, D.J. Barker, J.G. Eriksson.
Association of schizophrenia with low maternal body mass index, small size at birth, and thinness during childhood.
Arch Gen Psychiatry, 58 (2001), pp. 48-52
[9.]
M.C. Ryan, P. Collins, J.H. Thakore.
Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.
Am J Psychiatry, 160 (2003), pp. 284-289
[10.]
E. Fernandez-Egea, M. Bernardo, T. Donner, I. Conget, E. Parellada, A. Justicia, E. Esmatjes, C. Garcia-Rizo, B. Kirkpatrick.
The metabolic profile of antipsychotic-naïve patients with nonaffective psychosis.
Br J Psychiatry, 194 (2009), pp. 434-438
[11.]
B. Crespo-Facorro, E. Carrasco-Marín, R. Pérez-Iglesias, J.M. Pelayo-Terán, L. Fernandez-Prieto, F. Leyva-Cobián, J.L. Vázquez-Barquero.
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.
Psychiatry Res, 158 (2008), pp. 206-216
[12.]
E. Fernandez-Egea, M. Bernardo, C.M. Heaphy, J.K. Griffith, E. Parellada, E. Esmatjes, I. Conget, L. Nguyen, V. George, H. Stöppler, B. Kirkpatrick.
Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis.
Schizophr Bull, 35 (2009), pp. 437-442
[13.]
M.H. Rapaport, J.B. Lohr.
Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.
Acta Psychiatr Scand, 90 (1994), pp. 311-315
[14.]
D. Dickinson, J.M. Gold, F.B. Dickerson, D. Medoff, L.B. Dixon.
Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes.
Psychosomatics, 49 (2008), pp. 123-131
[15.]
S. Akhondzadeh, M. Tabatabaee, H. Amini, S.A. Ahmadi Abhari, S.H. Abbasi, B. Behnam.
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Schizophr Res, 90 (2007), pp. 179-185
[16.]
N. Müller, M. Ulmschneider, C. Scheppach, M.J. Schwarz, M. Ackenheil, H.J. Möller, R. Gruber, M. Riedel.
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.
Eur Arch Psychiatry Clin Neurosci, 254 (2004), pp. 14-22
[17.]
Fernandez-Egea E, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B. Stem cell signaling in newly diagnosed, antipsychotic-naïve subjects with nonaffective psychosis. Molecular Psychiatry, in press.
[18.]
E. Fernandez-Egea, M. Bernardo, E. Parellada, A. Justicia, C. Garcia-Rizo, E. Esmatjes, I. Conget, B. Kirkpatrick.
Glucose abnormalities in the siblings of people with schizophrenia.
Schizophr Res, 103 (2008), pp. 110-113
[19.]
E. Fernandez-Egea, B. Miller, M. Bernardo, T. Donner, B. Kirkpatrick.
Parental history of Type 2 diabetes in patients with nonaffective psychosis.
Schizophr Res, 98 (2008), pp. 302-306
[20.]
L.M. Spelman, P.I. Walsh, N. Sharifi, P. Collins, J.H. Thakore.
Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia.
Diabet Med, 24 (2007), pp. 481-485
[21.]
S. Saha, D. Chant, J. McGrath.
A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?.
Arch Gen Psychiatry, 64 (2007), pp. 1123-1131
Copyright © 2009. SEP y SEPB